RO-6885247

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameRO-6885247

Drug Alias NameSMN2 gene-targeted therapy - PTC TherapeuticsSMN2-targeted therapeutic for spinal muscular atrophy - PTC Therapeutics/SMA Foundation/RocheRG-7800RO-6885247

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSurvival motor neuron protein modulators

TargetsSurvival motor neuron protein

Therapy Area/IndicationsMuscular Atrophy, Spinal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSweden +[9]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPtc Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesF. Hoffmann-La Roche Ltd

Active IndicationsN/A

Inactive IndicationsMuscular Atrophy, Spinal

Other Information

ATC CodeN/A